Related Experiment Video

Updated: Aug 23, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

The effect of atorvastatin on platelet function in patients with coronary artery disease

Tarkan Tekten1, Ceyhun Ceyhan, Ertugrul Ercan

  • 1Adnan Menderes University Medical School, Cardiology Department, Aydin, Turkey. tarkantekten@superonline.com

Acta Cardiologica
|July 17, 2004
PubMed

Insights

Atorvastatin significantly reduced platelet aggregation in patients with coronary artery disease (CAD). This lipid-lowering therapy effectively lowered cholesterol levels and improved platelet response to ADP stimulation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Lipid-lowering therapy offers benefits for patients with coronary artery disease (CAD).
  • Platelet aggregation plays a critical role in CAD pathogenesis.
  • Statins are widely used for managing hypercholesterolemia.

Purpose of the Study:

  • To evaluate the impact of atorvastatin on platelet aggregation in CAD patients.
  • To assess changes in platelet response to various agonists after atorvastatin treatment.
  • To correlate lipid level changes with alterations in platelet activity.

Main Methods:

  • A study involving 25 hypercholesterolemic CAD patients and 16 healthy controls.
  • Two-month treatment with 10 mg/day atorvastatin in CAD patients.
  • Platelet aggregation measured using turbidimetric aggregometry in response to ADP, collagen, and epinephrine before and after therapy.

Main Results:

  • Atorvastatin therapy significantly reduced total cholesterol and LDL cholesterol levels (p < 0.05).
  • Platelet aggregation in response to adenosine diphosphate (ADP) significantly decreased post-treatment.
  • No significant changes in platelet aggregation were observed in response to collagen or epinephrine.

Conclusions:

  • Atorvastatin, an HMG-CoA reductase inhibitor, effectively reduces platelet aggregation in CAD patients.
  • The observed reduction in platelet aggregation is primarily linked to ADP-induced activation.
  • Lipid-lowering therapy with atorvastatin demonstrates anti-platelet effects beneficial in CAD management.
Abstract

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...